Peripheral Artery Disease

Highlights Hub

PAD News Digest

ADA 2021: Rivaroxaban Most Beneficial in Patients with Critical Limb Ischemia and Diabetes Mellitus

June 25, 2021 - In a new subgroup analysis of the VOYAGER-PAD trial presented at the 2021 American Diabetes Association (ADA) Scientific Sessions, authors reported that the benefits of rivaroxaban plus aspirin were consistent in PAD patients with critical limb ischemia (CLI) regardless of diabetes mellitus (DM) status. In this trial, 47% of CLI patients had comorbid DM, and the results of the analysis are important because the efficacy and safety of rivaroxaban in these patients was not established. However, because of baseline risk, the absolute benefit was greater in patients with both CLI and DM vs. those with CLI and without comorbid DM.

The full results of this analysis can be accessed here.

ACC 2021: Rivaroxaban Reduces Total Events Post Lower Extremity Revascularization

May 16, 2021 - The primary results of the VOYAGER-PAD trial showed that rivaroxaban 2.5mg twice daily plus aspirin, compared to placebo plus aspirin, reduced the risk of first events by about 15% in patients with peripheral artery disease (PAD) who underwent a lower extremity revascularization. The results of this secondary analysis of the VOYAGER-PAD trial showed that this approached also reduced the total event burden in these patients, including a 14% reduction in total primary events (included acute limb ischemia, major amputation of a vascular cause, nonfatal myocardial infarction, nonfatal ischemic stroke and cardiovascular death), and a 14% reduction in total vascular events (included peripheral revascularization and venous thromboembolic event).

To watch Drs. Bhatt, Bonaca, and Patel discuss these results, please click here.

The full results of this study can be accessed here.